A5064400662- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Inflammatory Bowel Disease
- Microscopic Colitis
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Acute Myocardial Infarction Research
- Medical Coding and Health Information
- Cardiac Imaging and Diagnostics
- Artificial Intelligence in Healthcare
- Primary Care and Health Outcomes
- Colorectal Cancer Screening and Detection
- Social Media in Health Education
- Aortic Thrombus and Embolism
- Eosinophilic Esophagitis
- Mental Health and Patient Involvement
- Patient-Provider Communication in Healthcare
- Mobile Health and mHealth Applications
- Antiplatelet Therapy and Cardiovascular Diseases
- Healthcare Policy and Management
- Healthcare Systems and Technology
- Computational Drug Discovery Methods
- Genetic Associations and Epidemiology
- Chronic Disease Management Strategies
- Biomedical and Engineering Education
Heart Foundation
2023
FH Foundation
2017-2022
Lymphoma Foundation
2019-2021
California University of Pennsylvania
2020
Baylor College of Medicine
2017
Stanford University
2017
Familial hypercholesterolemia (FH) is an underdiagnosed dominant genetic condition affecting approximately 0.4% of the population and has up to a 20-fold increased risk coronary artery disease if untreated. Simple screening strategies have false positive rates greater than 95%. As part FH Foundation's FIND initiative, we developed classifier identify potential patients using electronic health record (EHR) data at Stanford Health Care. We trained random forest from known (n = 197) matched...
Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels event rates. However, prescriptions are rejected at high rates by payers, use is often delayed or eventually abandoned as treatment option. We tested the hypothesis that acute coronary syndromes, interventions, stroke, cardiac...
Background Homozygous familial hypercholesterolemia (HoFH) is a rare, treatment‐resistant disorder characterized by early‐onset atherosclerotic and aortic valvular cardiovascular disease if left untreated. Contemporary information on HoFH in the United States lacking, extent of underdiagnosis undertreatment uncertain. Methods Results Data were analyzed from 67 children adults with clinically diagnosed CASCADE (Cascade Screening for Awareness Detection) FH Registry. Genetic diagnosis was...
BackgroundCardiovascular outcomes for people with familial hypercholesterolaemia can be improved diagnosis and medical management. However, 90% of individuals remain undiagnosed in the USA. We aimed to accelerate early timely intervention more than 1·3 million at high risk heart attacks strokes by applying machine learning large health-care encounter datasets.MethodsWe trained FIND FH model using deidentified data, including procedure diagnostic codes, prescriptions, laboratory findings,...
Implementation of the 2010 Affordable Care Act (ACA) calls for a collaborative effort to transform U.S. health care system toward patient-centered and value-based care. To identify how specialty can be improved, we mapped current utilization in patients with inflammatory bowel diseases (IBD) using national insurance claims database.We performed cross-sectional study analyzing 964,633 IBD between 2012 data, including pharmacy medical claims. Frequency IBD-related (medication, tests,...
The Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network (PPRN) seeks to advance accelerate comparative effectiveness translational research in inflammatory bowel diseases (IBDs). Our IBD-focused PCORnet PPRN has been designed overcome the major obstacles that have limited patient-centered outcomes IBD by providing technical infrastructure, patient governance, patient-driven functionality needed to: 1) identify, prioritize, undertake a agenda through sharing...
Background: Familial hypercholesterolemia (FH) is the most common cardiovascular genetic disorder and, if left untreated, associated with increased risk of premature atherosclerotic disease, leading cause preventable death in United States. Although FH common, fatal, and treatable, it underdiagnosed undertreated due to a lack systematic methods identify individuals limited uptake cascade testing. Methods Results: This mixed-method, multi-stage study will optimize, test, implement innovative...
Cardiovascular disease (CVD), hypertension, and heart failure are associated with higher rates of coronavirus 2019 (COVID-19) related morbidity mortality [ 1 , 2 ].However, studies have documented fewer individuals presenting to hospitals acute myocardial infarction (AMI) during the pandemic 3 4 ].To better understand impact COVID-19 on AMI in pre-existing atherosclerotic cardiovascular (ASCVD), familial hypercholesterolemia (FH), or both, FH Foundation performed an analysis a large...
Background Data mining of electronic health records to identify patients suspected familial hypercholesterolemia (FH) has been limited by absence both phenotypic and genomic data in the same cohort. Methods Results Using Geisinger MyCode Community Health Initiative cohort (n=130 257), we ran 2 screening algorithms (Mayo Clinic [Mayo] flag, identify, network, deliver [FIND] FH) determine FH genetic diagnostic yields. With 29 243 excluded Mayo (for secondary causes hypercholesterolemia, no...
Background: To build a Patient-Powered Research Networks (PPRN) that prioritizes the needs of its members who have inflammatory bowel diseases (IBD), we sought to better understand patients’ preferences for what are essential features will facilitate and sustain engagement. Methods: We conducted two-phase qualitative study. Seven focus groups involving 62 participants with IBD were (phase 1). Focus group results informed phase 2 cognitive interviews, which included 13 phone interviews....
ASCVD/CVD in Special Populations An ICD-10 code for Familial Hypercholesterolemia (FH), E78.01, became effective October 2016 following a proposal by the Family Heart Foundation. It differentiated FH from other forms of elevated cholesterol with goal increasing assessment this treatable genetic condition. Prior to <1% patients US were diagnosed (Nordestgarrd, 2013). This study aims characterize current number and percent E78.01 an expansive, real-world dataset. The Database includes 197...